Home / Health / New Drug Offers Hope Against Deadly Pancreatic Cancer
New Drug Offers Hope Against Deadly Pancreatic Cancer
8 May
Summary
- New drug daraxonrasib targets multiple RAS variants in cancer.
- Phase 3 trial shows 51% tumor reduction and 97% disease control.
- FDA grants daraxonrasib 'National Priority Voucher' for review.
A groundbreaking molecule named daraxonrasib has emerged as a potential game-changer in the fight against certain cancers. Developed by Revolution Medicines, this drug targets a broad range of RAS family proteins, including KRAS, which are crucial in regulating cell division.
The KRAS gene, identified in 1988 as frequently mutated in pancreatic cancers, has long been a difficult target for therapies. Daraxonrasib overcomes this challenge by binding indirectly to the active form of RAS proteins, effectively shutting down uncontrolled cell division.
Recent phase 3 clinical trial results, presented in April 2026, have been highly encouraging. The study found that daraxonrasib reduced tumor size in 51% of patients with advanced RAS-mutated cancers and brought the disease under control in 97%.
These promising outcomes have led the U.S. Food and Drug Administration (FDA) to grant daraxonrasib "National Priority Voucher" status, significantly accelerating its review timeline. While side effects like rash and diarrhea were reported, no life-threatening ones occurred, offering a significant ray of hope for patients, especially those with pancreatic cancer where treatment options are scarce.
